[go: up one dir, main page]

MA43605A1 - Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci - Google Patents

Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci

Info

Publication number
MA43605A1
MA43605A1 MA43605A MA43605A MA43605A1 MA 43605 A1 MA43605 A1 MA 43605A1 MA 43605 A MA43605 A MA 43605A MA 43605 A MA43605 A MA 43605A MA 43605 A1 MA43605 A1 MA 43605A1
Authority
MA
Morocco
Prior art keywords
isoquinolin
carboxamides
preparation
disease
treatment
Prior art date
Application number
MA43605A
Other languages
English (en)
Other versions
MA43605B1 (fr
Inventor
Sunil Kumar Kc
Gopi Kumar Mittapalli
Brian Joseph Hofilena
Chi Ching Mak
Joseph Timothy Marakovits
Chandramouli Chiruta
Jianguo Cao
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of MA43605A1 publication Critical patent/MA43605A1/fr
Publication of MA43605B1 publication Critical patent/MA43605B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés d'isoquinoline pour le traitement de diverses maladies et pathologies. La présente invention concerne plus particulièrement l'utilisation d'un composé d'isoquinoline ou d'analogues de celui-ci dans le traitement de troubles caractérisés par l'activation de la signalisation de la voie des wnt (par ex., le cancer, une prolifération cellulaire anormale, l'angiogenèse, la maladie d'alzheimer, la pneumopathie, l'inflammation, les maladies auti-immunes et l'arthrose), la modula
MA43605A 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci MA43605B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
PCT/US2017/029797 WO2017189823A2 (fr) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
MA43605A1 true MA43605A1 (fr) 2020-04-30
MA43605B1 MA43605B1 (fr) 2020-10-28

Family

ID=60157342

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43605A MA43605B1 (fr) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci

Country Status (19)

Country Link
US (5) US10508099B2 (fr)
EP (2) EP3943086A1 (fr)
JP (1) JP7023243B2 (fr)
KR (1) KR102399206B1 (fr)
CN (1) CN109311819B (fr)
AR (1) AR108326A1 (fr)
AU (1) AU2017258187B2 (fr)
BR (1) BR112018072190A2 (fr)
CA (1) CA3022044A1 (fr)
CL (2) CL2018003050A1 (fr)
CO (1) CO2018012655A2 (fr)
IL (1) IL262495B (fr)
MA (1) MA43605B1 (fr)
MX (1) MX386319B (fr)
PE (1) PE20190260A1 (fr)
PH (1) PH12018502259A1 (fr)
RU (1) RU2018141379A (fr)
SG (2) SG11201809310PA (fr)
WO (1) WO2017189823A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP4067347B1 (fr) * 2016-05-24 2024-06-19 Genentech, Inc. Inhibiteurs hétérocycliques de cbp/ep300 pour le traitement du cancer
WO2018183964A1 (fr) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
WO2019079410A1 (fr) * 2017-10-17 2019-04-25 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
WO2019079626A1 (fr) * 2017-10-19 2019-04-25 Samumed, Llc 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2019084497A1 (fr) 2017-10-27 2019-05-02 Samumed, Llc 6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
WO2019089835A1 (fr) * 2017-10-31 2019-05-09 Samumed, Llc Diazanaphthalèn-3-yl carboxamides, préparation et utilisation de ceux-ci
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
EP3790865A1 (fr) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Pyrazoles substitués par phényle utilisés en tant que modulateurs de roryt
CN112601584A (zh) 2018-07-24 2021-04-02 豪夫迈·罗氏有限公司 异喹啉化合物及其用途
TW202024053A (zh) * 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (fr) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de hpk1
US20230090255A1 (en) * 2019-09-05 2023-03-23 Lunan Pharmaceutical Group Corporation Magl inhibitor, preparation method therefor and use thereof
US20230303552A1 (en) * 2020-06-19 2023-09-28 Vanderbilt University Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor m5 inhibitors
WO2022093881A1 (fr) * 2020-10-29 2022-05-05 Merck Sharp & Dohme Corp. Amides isoquinoline liés à n en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations associées
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
WO2023055679A1 (fr) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc Amides isoquinoline liés à c en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations associées
IL313539A (en) * 2021-12-10 2024-08-01 Prothena Biosciences Ltd Methods for treating neurological disorders
TW202506660A (zh) * 2023-04-27 2025-02-16 美商塞普特納公司 Mrgprx2拮抗劑及其使用方法
KR20240162928A (ko) 2023-05-09 2024-11-18 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP1861161A4 (fr) 2005-01-24 2012-05-16 Neurosystec Corp Appareil et methode permettant de distribuer des agents therapeutiques et/ou autres a l'oreille interne et a d'autres tissus
WO2007125405A2 (fr) * 2006-05-01 2007-11-08 Pfizer Products Inc. Composés hétérocycliques 2-amino-substitués à cycles fusionnés
CN101821279A (zh) * 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
EP2464232B1 (fr) * 2009-08-10 2015-10-07 Samumed, LLC Composés d indazole inhibant la voie de signalisation des wnt et utilisations thérapeutiques de ceux-cithereof
CA2770320A1 (fr) 2009-08-10 2011-02-17 Epitherix, Llc Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/beta-catenine et utilisations therapeutiques de ceux-ci
MX2012010666A (es) * 2010-03-31 2012-10-05 Actelion Pharmaceuticals Ltd Derivados de isoquinolin-3-ilurea antibacterianos.
KR20130129244A (ko) 2010-12-17 2013-11-27 에프. 호프만-라 로슈 아게 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
IN2014CN02646A (fr) 2011-09-14 2015-08-07 Samumed Llc
WO2013169793A2 (fr) * 2012-05-09 2013-11-14 Ipierian, Inc. Procédés et compositions pour des protéinopathies tdp-43
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
SG10201914111XA (en) 2014-03-20 2020-03-30 Samumed Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US20220062240A1 (en) 2018-06-26 2022-03-03 Biosplice Therapeutics, Inc. Methods of treating cancer using a clk inhibitor

Also Published As

Publication number Publication date
IL262495B (en) 2021-12-01
US20170313681A1 (en) 2017-11-02
US10556885B2 (en) 2020-02-11
US20230104155A1 (en) 2023-04-06
PH12018502259A1 (en) 2019-06-10
KR102399206B1 (ko) 2022-05-17
BR112018072190A2 (pt) 2019-02-12
MX386319B (es) 2025-03-18
JP2019515931A (ja) 2019-06-13
US11174244B2 (en) 2021-11-16
RU2018141379A (ru) 2020-05-28
EP3448838A4 (fr) 2019-12-25
CN109311819B (zh) 2022-10-25
RU2018141379A3 (fr) 2020-08-13
MA43605B1 (fr) 2020-10-28
WO2017189823A2 (fr) 2017-11-02
AU2017258187A1 (en) 2018-11-15
US20180208580A1 (en) 2018-07-26
CA3022044A1 (fr) 2017-11-02
PE20190260A1 (es) 2019-02-25
AR108326A1 (es) 2018-08-08
US10287267B2 (en) 2019-05-14
CL2018003050A1 (es) 2019-01-25
SG10201914127PA (en) 2020-02-27
KR20190012167A (ko) 2019-02-08
AU2017258187B2 (en) 2021-08-26
US20180222887A1 (en) 2018-08-09
MX2018013173A (es) 2019-02-13
CO2018012655A2 (es) 2019-04-30
IL262495A (en) 2018-12-31
EP3448838A2 (fr) 2019-03-06
EP3943086A1 (fr) 2022-01-26
WO2017189823A3 (fr) 2018-02-08
EP3448838B1 (fr) 2021-08-11
SG11201809310PA (en) 2018-11-29
US11673881B2 (en) 2023-06-13
US10508099B2 (en) 2019-12-17
CN109311819A (zh) 2019-02-05
JP7023243B2 (ja) 2022-02-21
US20200339536A1 (en) 2020-10-29
CL2019002067A1 (es) 2020-07-10

Similar Documents

Publication Publication Date Title
MA43605B1 (fr) Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci
MA43619A1 (fr) Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci
MA37450A1 (fr) Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA46018A (fr) Activateurs d'édition du génome
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
TN2009000551A1 (fr) Nouveaux composes chimiques
MA52747A (fr) Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
MA41758B1 (fr) Procédés de traitement de l'infertilité
MA44948A1 (fr) Inhibiteurs de bace 1
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
EP3723768A4 (fr) Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
MA31198B1 (fr) Nouvelle forme dosifiee
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
MA45803B1 (fr) Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage
MX2020005238A (es) Compuestos novedosos como inhibidores mpges-1.
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
FR3088542B1 (fr) Composition cicatrisante comprenant une eau électrolysée